循环肿瘤细胞在前列腺癌中的应用

摘要/Abstract

摘要：

近年来，循环肿瘤细胞（circulating tumor cell， CTC）检测平台取得了巨大进步，实现了从简单的CTC计数到分子分析等的跨越。目前的研究重点是将CTC检测应用于转移性去势抵抗性前列腺癌（metastatic castration‐resistant prostate cancer， mCRPC）阶段，将CTC检测与基因检测等技术其结合，与特定基因［如AR、雄激素受体剪切突变体7（androgen receptor variant 7， AR‐V7）等］表达的测定相结合，以研究其在风险评估、治疗功效监测、耐药性监测、转移预测、预后预测等多方面的作用。CTC检测在前列腺癌诊断和治疗中发挥重要作用，是前列腺癌最具前景的无创检测技术之一。本文就CTC检测与前列腺癌诊疗及预后相关的研究进展进行系统综述，为前列腺癌的临床诊断与治疗提供参考。

关键词:循环肿瘤细胞,前列腺癌,CTC检测平台,雄激素受体剪切突变体7

Abstract:

CTC detection has made a great progress from CTC counting to molecular analysis in recent years. The current research is mainly to apply CTC detection to predict the drug sensitivity of advanced prostate cancer and guide treatment and prognosis evaluation. The current research focus is to apply CTC detection to the mCRPC stage， combining CTC detection with gene detection and other technologies， and with the detection of specific gene （such asAR，AR-V7， etc.） expression to study its role in drug resistance mechanism and guiding mCRPC treatment and prognosis prediction. CTC detection plays an important role in the diagnosis and treatment of prostate cancer， and it is one of the most promising non-invasive detection techniques for prostate cancer. This article reviews the progress of CTC detection in the diagnosis， treatment and prognosis of prostate cancer， which can provide reference for the clinical diagnosis and treatment of prostate cancer.

Key words:circulating tumor cell,prostate cancer,CTC detection platform,AR-V7

韩明帅, 武英欣, 金讯波. 循环肿瘤细胞在前列腺癌中的应用[J]. betway必威登陆网址（betway.com ）学报, 2023, 44(8): 613-617.

Mingshuai HAN, Yingxin WU, Xunbo JIN. Application of circulating tumor cell in prostate cancer[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2023, 44(8): 613-617.

参考文献43

1	Siegel RL， Miller KD， Jemal A. Cancer statistics， 2020［J］. CA Cancer J Clin， 2020， 70（1）： 7.
2	Bray F， Ferlay J， Soerjomataram I， et al. Global cancer statistics 2018： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin， 2108， 68（6）： 394.
3	Scher HI， Lu D， Schreiber NA， et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer［J］. JAMA Oncol， 2016， 2（11）： 1441.
4	De Bono JS， Scher HI， Montgomery RB， et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer［J］. Clin Cancer Res， 2008， 14（19）： 6302.
5	Theil G， Boehm C， Fischer K， et al. In vivo isolation of circulating tumor cells in patients with different stages of prostate cancer［J］. Oncol Lett， 2021， 21（5）： 357.
6	Baca SC， Prandi D， Lawrence MS， et al. Punctuated evolution of prostate cancer genomes［J］. Cell， 2013， 153（3）： 666.
7	Hofman P， Popper HH. Pathologists and liquid biopsies： to be or not to be？［J］. Virchows Arch， 2016， 469（6）： 601.
8	Alix-Panabières C， Pantel K. Circulating tumor cells： liquid biopsy of cancer［J］. Clin Chem， 2013， 59（1）： 110.
9	Ferreira MM， Ramani VC， Jeffrey SS. Circulating tumor cell technologies［J］. Mol Oncol， 2016， 10（3）： 374.
10	Cristofanilli M， Budd GT， Ellis MJ， et al. Circulating tumor cells， disease progression， and survival in metastatic breast cancer［J］. N Engl J Med， 2004， 351（8）： 781.
11	Habli Z， AlChamaa W， Saab R， et al. Circulating tumor cell detection technologies and clinical utility： challenges and opportunities［J］. Cancers （Basel）， 2020， 12（7）： 1930.
12	Wang L， Balasubramanian P， Chen AP， et al. Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells［J］. Semin Oncol， 2016， 43（4）： 464.
13	Hong B， Zu Y. Detecting circulating tumor cells： current challenges and new trends［J］. Theranostics， 2013， 3（6）： 377.
14	Müller V， Riethdorf S， Rack B， et al. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients： the DETECT study［J］. Breast Cancer Res， 2012， 14（4）： R118.
15	Danila DC， Samoila A， Patel C， et al. Clinical validity of detecting circulating tumor cells by AdnaTest assay compared with direct detection of tumor mRNA in stabilized whole blood， as a biomarker predicting overall survival for metastatic castration-resistant prostate cancer patients［J］. Cancer J， 2016， 22（5）： 315.
16	Van Der Auwera I， Peeters D， Benoy IH， et al. Circulating tumour cell detection： a direct comparison between the CellSearch System， the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer［J］. Br J Cancer， 2010， 102（2）： 276.
17	Scherag FD， Niestroj-Pahl R， Krusekopf S， et al. Highly selective capture surfaces on medical wires for fishing tumor cells in whole blood［J］. Anal Chem， 2017， 89（3）： 1846.
18	Dong Y， Skelley AM， Merdek KD， et al. Microfluidics and circulating tumor cells［J］. J Mol Diagn， 2013， 15（2）： 149.
19	Zou D， Cui D. Advances in isolation and detection of circulating tumor cells based on microfluidics［J］. Cancer Biol Med， 2018， 15（4）： 335.
20	Svobodova Z， Kucerova J， Autebert J， et al. Application of an improved magnetic immunosorbent in an Ephesia chip designed for circulating tumor cell capture［J］. Electrophoresis， 2014， 35（2/3）： 323.
21	Maas M， Hegemann M， Rausch S， et al. Circulating tumor cells and their role in prostate cancer［J］. Asian J Androl， 2017， 21（1）： 24.
22	Meyer CP， Pantel K， Tennstedt P， et al. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer［J］. Urol Oncol， 2016， 34（5）： 235.e11.
23	Mandel PC， Huland H， Tiebel A， et al. Enumeration and changes in circulating tumor cells and their prognostic value in patients undergoing cytoreductive radical prostatectomy for oligometastatic prostate cancer-translational research results from the prospective ProMPT trial［J］. Eur Urol Focus， 2021， 7（1）： 55.
24	Tsumura H， Satoh T， Ishiyama H， et al. Perioperative search for circulating tumor cells in patients undergoing prostate brachytherapy for clinically nonmetastatic prostate cancer［J］. Int J Mol Sci， 2017， 18（1）： 128.
25	Thalgott M， Rack B， Horn T， et al. Detection of circulating tumor cells in locally advanced high-risk prostate cancer during neoadjuvant chemotherapy and radical prostatectomy［J］. Anticancer Res， 2015， 35（10）： 5679.
26	Stott SL， Lee RJ， Nagrath S， et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer［J］. Sci Transl Med， 2010， 2（25）： 25ra23.
27	Theil G， Lindner C， Bialek J， et al. Association of circulating tumor cells with inflammatory and biomarkers in the blood of patients with metastatic castration-resistant prostate cancer［J］. Life （Basel）， 2021， 11（7）： 664.
28	Kuske A， Gorges TM， Tennstedt P， et al. Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients［J］. Sci Rep， 2016， 6： 39736.
29	Danila DC， Heller G， Gignac GA， et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer［J］. Clin Cancer Res， 2007， 13（23）： 7053.
30	Cohen SJ， Punt CJ， Iannotti N， et al. Relationship of circulating tumor cells to tumor response， progression-free survival， and overall survival in patients with metastatic colorectal cancer［J］. J Clin Oncol， 2008， 26（19）： 3213.
31	Kozminsky M， Fouladdel S， Chung JS， et al. Detection of CTC clusters and a dedifferentiated RNA-expression survival signature in prostate cancer［J］. Adv Sci （Weinh）， 2019， 6（2）： 1801254.
32	De Wit S， Manicone M， Rossi E， et al. EpCAMhigh and EpCAMlow circulating tumor cells in metastatic prostate and breast cancer patients［J］. Oncotarget， 2018， 9（86）： 35705.
33	Agerbæk MØ， Bang-Christensen SR， Yang MH， et al. The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner［J］. Nat Commun， 2018， 9（1）： 3279.
34	Jan YJ， Yoon J， Chen JF， et al. A circulating tumor Cell-RNA assay for assessment of androgen receptor signaling inhibitor sensitivity in metastatic castration-resistant prostate cancer［J］. Theranostics， 2019， 9（10）： 2812.
35	Wark L， Quon H， Ong A， et al. Long-term dynamics of three dimensional telomere profiles in circulating tumor cells in high-risk prostate cancer patients undergoing androgen-deprivation and radiation therapy［J］. Cancers （Basel）， 2019， 11（8）： 1165.
36	Tsao CK， Small AC， Galsky MD， et al. Overcoming castration resistance in prostate cancer［J］. Curr Opin Urol， 2012， 22（3）： 167.
37	Nakazawa M， Paller C， Kyprianou N. Mechanisms of therapeutic resistance in prostate cancer［J］. Curr Oncol Rep， 2017， 19（2）： 13.
38	Bastos DA， Antonarakis ES. CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer［J］. Expert Rev Mol Diagn， 2018， 18（2）： 155.
39	Cattrini C， Rubagotti A， Zinoli L， et al. Role of circulating tumor cells （CTC）， androgen receptor full length （AR-FL） and androgen receptor splice variant 7 （AR-V7） in a prospective cohort of castration-resistant metastatic prostate cancer patients［J］. Cancers （Basel）， 2019， 11（9）： 1365.
40	Antonarakis ES， Lu C， Luber B， et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide［J］. J Clin Oncol， 2017， 35（19）： 2149.
41	Nimir M， Ma Y， Jeffreys SA， et al. Detection of AR-V7 in liquid biopsies of castrate resistant prostate cancer patients： a comparison of AR-V7 analysis in circulating tumor cells， circulating tumor RNA and exosomes［J］. Cells， 2019， 8（7）： 688.
42	Del Re M， Crucitta S， Sbrana A， et al. Androgen receptor （AR） splice variant 7 and full-length AR expression is associated with clinical outcome： a translational study in patients with castrate-resistant prostate cancer［J］. BJU Int， 2019， 124（4）： 693.
43	Scher HI， Graf RP， Schreiber NA， et al. Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer［J］. JAMA Oncol， 2018， 4（9）： 1179.

[1]	王伟浩, 马莹, 李胜.循环肿瘤细胞形态诊断参数测量方法的研究进展[J]. betway必威登陆网址（betway.com ）学报, 2023, 44(8): 561-564.
[2]	张亚飞, 黄冉冉, 张国伟.磁共振成像在前列腺癌早期筛查中的应用价值[J]. betway必威登陆网址（betway.com ）学报, 2022, 43(12): 963-971.